Literature DB >> 7957351

Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.

M Duet1, O Mundler, C Ajzenberg, B Berolatti, P Chedin, L Duranteau, A Warnet.   

Abstract

Somatostatin receptor imaging (SRI) was performed in five patients with known non-functioning pituitary adenomas. To determine whether the pituitary uptake correlates with response to octreotide therapy, an uptake index (UI) was calculated. Pituitary adenomas were detected in all five patients. The UI was, respectively, 15.1, 3.7, 2.2, 2.2 and 2.2 (the UI calculated in 12 normal subjects was between 1 and 1.9). Only the patient with the highest UI (15.1) had a dramatic improvement in tumour volume and visual function in response to octreotide therapy. The UI might be a good predictive parameter of octreotide therapy efficacy in non-functioning adenomas.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7957351     DOI： 10.1007/BF00285587

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  11 in total

Review 1.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Authors:  S W Lamberts; E P Krenning; J C Reubi
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

2.  Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro.

Authors:  A Klibanski; J M Alexander; H A Bikkal; D W Hsu; B Swearingen; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1991-12       Impact factor: 5.958

3.  The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas.

Authors:  A Warnet; J Timsit; P Chanson; P J Guillausseau; F Zamfirescu; A G Harris; P Derome; J Cophignon; J Lubetzki
Journal:  J Neurosurg       Date:  1989-11       Impact factor: 5.115

4.  Specific somatostatin receptors on human pituitary adenoma cell membranes.

Authors:  S Ikuyama; H Nawata; K Kato; T Karashima; H Ibayashi; H Nakagaki
Journal:  J Clin Endocrinol Metab       Date:  1985-10       Impact factor: 5.958

Review 5.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

6.  Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.

Authors:  J Bertherat; T Brue; A Enjalbert; G Gunz; R Rasolonjanahary; A Warnet; P Jaquet; J Epelbaum
Journal:  J Clin Endocrinol Metab       Date:  1992-08       Impact factor: 5.958

7.  Somatostatin and Thyrotrophin-Releasing Hormone Response and Receptor Status of a Thyrotrophin-Secreting Pituitary Adenoma: Clinical and in vitro Studies.

Authors:  A Levy; D J Eckland; A M Gurney; J C Reubi; R Doshi; S L Lightman
Journal:  J Neuroendocrinol       Date:  1989-10-01       Impact factor: 3.627

8.  Octreotide treatment does not affect the size of most non-functioning pituitary adenomas.

Authors:  M Gasperi; L Petrini; R Pilosu; M Nardi; A Marcello; F Mastio; L Bartalena; E Martino
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

9.  Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: evidence of a positive correlation with tumour volume in men.

Authors:  N Lahlou; E Le Nestour; P Chanson; D Seret-Bégué; P Bouchard; M Roger; A Warnet
Journal:  Clin Endocrinol (Oxf)       Date:  1993-03       Impact factor: 3.478

10.  Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.

Authors:  T W de Bruin; D J Kwekkeboom; J W Van't Verlaat; J C Reubi; E P Krenning; S W Lamberts; R J Croughs
Journal:  J Clin Endocrinol Metab       Date:  1992-11       Impact factor: 5.958
View more
  6 in total

Review 1.  Receptor imaging in the diagnosis and treatment of pituitary tumors.

Authors:  D J Kwekkeboom; W W de Herder; E P Krenning
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.

Authors:  S Nielsen; S Mellemkjaer; L M Rasmussen; T Ledet; N Olsen; M Bojsen-Møller; J Astrup; J Weeke; J O Jørgensen
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

Review 3.  Somatostatin receptor SPECT.

Authors:  Giovanna Pepe; Roy Moncayo; Emilio Bombardieri; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

4.  111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.

Authors:  P Legovini; E De Menis; D Billeci; B Conti; P Zoli; N Conte
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

5.  Somatostatin receptor scintigraphy in patients with pituitary adenoma.

Authors:  A Rieger; N G Rainov; C Elfrich; M Klaua; H Meyer; C Lautenschläger; W Burkert; T Mende
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

Review 6.  Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas.

Authors:  Annamaria Colao; Mariagiovanna Filippella; Carolina Di Somma; Simona Manzi; Francesca Rota; Rosario Pivonello; Maria Gaccione; Michele De Rosa; Gaetano Lombardi
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.